Detalles de la búsqueda
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer;
154(6): 1043-1056, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37994647
2.
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.
Clin Gastroenterol Hepatol;
22(1): 72-80.e4, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37442316
3.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int;
44(1): 113-124, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37789669
4.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int;
44(5): 1108-1125, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517286
5.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res;
54(4): 382-391, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37983642
6.
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
J Gastroenterol Hepatol;
2024 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38602340
7.
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
J Gastroenterol Hepatol;
39(5): 949-954, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38291715
8.
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Cancer;
129(4): 590-599, 2023 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36426410
9.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology;
101(4): 270-282, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36455517
10.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology;
101(10): 624-633, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307798
11.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology;
101(9): 542-552, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552968
12.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology;
101(5): 283-291, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36657420
13.
A feasibility study comparing gel immersion endoscopic resection and underwater endoscopic mucosal resection for superficial nonampullary duodenal epithelial tumors.
Endoscopy;
55(3): 261-266, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35970190
14.
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.
BMC Gastroenterol;
23(1): 70, 2023 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36906542
15.
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
BMC Gastroenterol;
23(1): 101, 2023 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37003980
16.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res;
53(8): 737-748, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37020416
17.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res;
53(10): 1031-1042, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37306040
18.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol;
38(8): 1389-1397, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37231943
19.
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
Oncology;
100(2): 65-73, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34844247
20.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology;
100(12): 645-654, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36103846